Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Lantheus Holdings, Inc., AtriCure or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Lantheus Holdings, Inc., AtriCure and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Lantheus Holdings, Inc., AtriCure and Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Latest Health Care Equipment & Supplies and Lantheus Holdings, Inc., AtriCure, Inc. Stock News

As of December 10, 2025, Lantheus Holdings, Inc. had a $4.0 billion market capitalization, compared to the Health Care Equipment & Supplies median of $311.5 million. Lantheus Holdings, Inc.’s stock is down 29.5% in 2025, up 2% in the previous five trading days and down 31.66% in the past year.

Currently, Lantheus Holdings, Inc.’s price-earnings ratio is 25.4. Lantheus Holdings, Inc.’s trailing 12-month revenue is $1.5 billion with a 11.0% net profit margin. Year-over-year quarterly sales growth most recently was 1.4%. Analysts expect adjusted earnings to reach $5.588 per share for the current fiscal year. Lantheus Holdings, Inc. does not currently pay a dividend.

As of December 10, 2025, AtriCure, Inc. had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. AtriCure, Inc.’s stock is up 35.5% in 2025, up 5.5% in the previous five trading days and up 20.23% in the past year.

Currently, AtriCure, Inc. does not have a price-earnings ratio. AtriCure, Inc.’s trailing 12-month revenue is $518.3 million with a -5.6% net profit margin. Year-over-year quarterly sales growth most recently was 15.9%. Analysts expect adjusted earnings to reach $-0.239 per share for the current fiscal year. AtriCure, Inc. does not currently pay a dividend.

How We Compare Lantheus Holdings, Inc., AtriCure and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Lantheus Holdings, Inc., AtriCure and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Lantheus Holdings, Inc., AtriCure and Inc. Stock Value Grades

Company	Ticker	Value
Lantheus Holdings, Inc.	LNTH	C
AtriCure, Inc.	ATRC	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Lantheus Holdings, Inc. has a Value Score of 48, which is Average. AtriCure, Inc. has a Value Score of 15, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Lantheus Holdings, Inc., AtriCure or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Lantheus Holdings, Inc., AtriCure or Inc. is the better investment when it comes to value.

Lantheus Holdings, Inc., AtriCure and Inc. Growth Grades

Company	Ticker	Growth
Lantheus Holdings, Inc.	LNTH	B
AtriCure, Inc.	ATRC	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Lantheus Holdings, Inc. has a Growth Score of 62, which is Strong. AtriCure, Inc. has a Growth Score of 48, which is Average.

The Growth Grade Winner: Lantheus Holdings, Inc.

As you can clearly see from the Growth Grade breakdown above, Lantheus Holdings, Inc. has a more attractive growth grade than AtriCure, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Lantheus Holdings, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Lantheus Holdings, Inc., AtriCure and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Lantheus Holdings, Inc.	LNTH	D
AtriCure, Inc.	ATRC	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Lantheus Holdings, Inc. has a Earnings Estimate Score of 26, which is Negative. AtriCure, Inc. has a Earnings Estimate Score of 77, which is Positive.

The Earnings Estimate Revisions Grade Winner: AtriCure, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, AtriCure, Inc. has a better Earnings Estimate Revisions Grade than Lantheus Holdings, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, AtriCure, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Lantheus Holdings, Inc., AtriCure and Inc. Grades

In addition to Estimate Revisions, Growth and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Lantheus Holdings, Inc., AtriCure and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Lantheus Holdings, Inc., AtriCure or Inc. Stock?

Overall, Lantheus Holdings, Inc. stock has a Value Score of 48, Growth Score of 62 and Estimate Revisions Score of 26.

AtriCure, Inc. stock has a Value Score of 15, Growth Score of 48 and Estimate Revisions Score of 77.

Comparing Lantheus Holdings, Inc., AtriCure and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.